269 related articles for article (PubMed ID: 34059941)
1. L-asparaginase production review: bioprocess design and biochemical characteristics.
Castro D; Marques ASC; Almeida MR; de Paiva GB; Bento HBS; Pedrolli DB; Freire MG; Tavares APM; Santos-Ebinuma VC
Appl Microbiol Biotechnol; 2021 Jun; 105(11):4515-4534. PubMed ID: 34059941
[TBL] [Abstract][Full Text] [Related]
2. Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.
Miranda J; Lefin N; Beltran JF; Belén LH; Tsipa A; Farias JG; Zamorano M
BioDrugs; 2023 Nov; 37(6):793-811. PubMed ID: 37698749
[TBL] [Abstract][Full Text] [Related]
3. L-asparaginase from
Saeed H; Elsawy E; Shalaby M; Abdel-Fattah M; Hemida A; Eldoksh A; Ataya FS; Nematalla H; Elkewedi M; Labrou NN; El-Nikhely N
Prep Biochem Biotechnol; 2022; 52(6):668-680. PubMed ID: 34612174
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications.
Chand S; Mahajan RV; Prasad JP; Sahoo DK; Mihooliya KN; Dhar MS; Sharma G
Biotechnol Appl Biochem; 2020 Jul; 67(4):619-647. PubMed ID: 31954377
[TBL] [Abstract][Full Text] [Related]
5. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
6. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
Schnuchel A; Radcke C; Theobald L; Doeding S
PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
[TBL] [Abstract][Full Text] [Related]
7. Microbial production, molecular modification, and practical application of l-Asparaginase: A review.
Wang Y; Xu W; Wu H; Zhang W; Guang C; Mu W
Int J Biol Macromol; 2021 Sep; 186():975-983. PubMed ID: 34293360
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
[TBL] [Abstract][Full Text] [Related]
9. In Silico Design of a Chimeric Humanized L-asparaginase.
Pedroso A; Herrera Belén L; Beltrán JF; Castillo RL; Pessoa A; Pedroso E; Farías JG
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108713
[TBL] [Abstract][Full Text] [Related]
10. Microbial L-asparaginase as a promising enzyme for treatment of various cancers.
Darvishi F; Jahanafrooz Z; Mokhtarzadeh A
Appl Microbiol Biotechnol; 2022 Sep; 106(17):5335-5347. PubMed ID: 35871694
[TBL] [Abstract][Full Text] [Related]
11. Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase
Tong WH; Rizzari C
Haematologica; 2023 Oct; 108(10):2606-2615. PubMed ID: 37470157
[TBL] [Abstract][Full Text] [Related]
12. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase.
Patel N; Krishnan S; Offman MN; Krol M; Moss CX; Leighton C; van Delft FW; Holland M; Liu J; Alexander S; Dempsey C; Ariffin H; Essink M; Eden TO; Watts C; Bates PA; Saha V
J Clin Invest; 2009 Jul; 119(7):1964-73. PubMed ID: 19509471
[TBL] [Abstract][Full Text] [Related]
13. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
[TBL] [Abstract][Full Text] [Related]
15. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
[TBL] [Abstract][Full Text] [Related]
16. A new extracellular glutaminase and urease-free L-asparaginase from Meyerozyma guilliermondii.
Ratuchne A; Izidoro SC; Beitel SM; Lacerda LT; Knob A
Braz J Microbiol; 2023 Jun; 54(2):715-723. PubMed ID: 36917331
[TBL] [Abstract][Full Text] [Related]
17. Expanding targets for a metabolic therapy of cancer: L-asparaginase.
Covini D; Tardito S; Bussolati O; Chiarelli LR; Pasquetto MV; Digilio R; Valentini G; Scotti C
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):4-13. PubMed ID: 21854356
[TBL] [Abstract][Full Text] [Related]
18. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
[TBL] [Abstract][Full Text] [Related]
19. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.
Raetz EA; Salzer WL
J Pediatr Hematol Oncol; 2010 Oct; 32(7):554-63. PubMed ID: 20724951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
